Resources

CELEBREX resources

eDetail Presentations

View 3 quick presentations about treating arthritis patients with considerations such as GI intolerability, low-dose aspirin use, or aged 65 years or older.

Go

CELEBREX samples (log-in required)

Sign in or register to find out if you're eligible to receive CELEBREX samples.

Go

Dosing card

Get a 1-page dosing reference for CELEBREX.

Download

CELEBREX patient site

CELEBREX.com provides information about OA, RA, and treatment of symptoms with CELEBREX. You may also be able to watch the latest CELEBREX TV commercial.

Go

CELEBREX patient brochure

This handout offers information about OA, RA, and treatment of symptoms with CELEBREX, as well as an integrated approach to managing arthritis pain, including medication, lifestyle, and nutrition.

Download

Disease state information

OA and RA diagrams

Print these illustrations to help your patients understand
OA and RA.

Coverage and patient assistance

Savings card (log-in required)

Now your patients pay no more than $15* on their prescription. Find out if you are eligible to receive CELEBREX Savings Cards for your patients. *Terms and conditions apply.

Go

PfizerFormularyPro

Access up-to-date CELEBREX formulary information and prior authorization (PA) forms at PfizerFormularyPro.com.

Go

Pfizer Helpful Answers

Regardless of a patient's insurance situation, Pfizer Helpful Answers may be able to help.

Pfizer Helpful Answers is a family of prescription assistance programs that provides eligible patients with their Pfizer prescriptions for free or at a savings, and, in some cases, offers reimbursement support services.

  • Connection to Care®: A program that helps patients get their Pfizer prescriptions for free through their doctor's office.
  • Pfizer Pfriends®: A program designed to help uninsured patients save on their Pfizer prescriptions right at the pharmacy, regardless of their income.

Refer your patients to PHAHelps.com to learn more.

Go

Card will be accepted only at participating pharmacies. This card is not health insurance. No membership fees apply. For more information call 1-866-965-2200 or contact Pfizer at PO Box 29387, Mission, KS 66201.

The Pfizer Pfriends savings program is not health insurance. For a complete list of participating pharmacies, please click here or call the toll-free number 866-706-2400. There are no membership fees to participate in the Pfizer Pfriends program. Estimated savings range up to 15-36% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.

Important Safety Information

Cardiovascular Risk

  • CELEBREX may cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All nonsteroidal anti-inflammatory drugs (NSAIDs) may have a similar risk. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk.
  • CELEBREX is contraindicated for the treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.

Gastrointestinal Risk

  • NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

CELEBREX is contraindicated in patients with active gastrointestinal bleeding; in patients who have demonstrated allergic-type reactions to sulfonamides; or in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.

Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

As with all NSAIDs, CELEBREX can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Blood pressure should be monitored closely with all NSAIDs.

Fluid retention and edema have been observed in some patients taking NSAIDs, including CELEBREX. NSAIDs should be used with caution in patients with fluid retention or heart failure.

NSAIDs, including CELEBREX, may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors and angiotensin II antagonists, and in some patients can reduce the natriuretic effect of furosemide and thiazides.

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, may result in deterioration of renal function, including possible acute renal failure. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

CELEBREX can be used with low-dose aspirin. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.

Concomitant administration of aspirin with CELEBREX increases the rate of GI ulceration or other complications, compared with use of CELEBREX alone.

Treatment with NSAIDs, including CELEBREX, is not recommended in those patients with advanced renal disease. In addition, NSAIDs may cause renal toxicity.

Serious skin reactions such as exfoliative dermatitis, Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported in patients receiving CELEBREX. These reactions can be fatal. They can occur without warning and in patients without prior known sulfa allergy. CELEBREX should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Rare cases of anaphylactic reactions and angioedema have been reported in patients receiving CELEBREX. Patients should seek immediate emergency assistance if they have swelling of the face or throat or have difficulty breathing.

CELEBREX should be avoided in late pregnancy.

NSAIDs, including CELEBREX, should be used with caution in pediatric patients with systemic onset JRA, due to the risk of disseminated intravascular coagulation.

Please see Full Prescribing Information including boxed warning

Indications

CELEBREX is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults; the treatment of primary dysmenorrhea; and for relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older.

Please scroll for Important Safety Information and Indication

Important Safety Information

Cardiovascular Risk

  • CELEBREX may cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All nonsteroidal anti-inflammatory drugs (NSAIDs) may have a similar risk. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk.
  • CELEBREX is contraindicated for the treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.

Gastrointestinal Risk

  • NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

CELEBREX is contraindicated in patients with active gastrointestinal bleeding; in patients who have demonstrated allergic-type reactions to sulfonamides; or in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.

Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

As with all NSAIDs, CELEBREX can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Blood pressure should be monitored closely with all NSAIDs.

Fluid retention and edema have been observed in some patients taking NSAIDs, including CELEBREX. NSAIDs should be used with caution in patients with fluid retention or heart failure.

NSAIDs, including CELEBREX, may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors and angiotensin II antagonists, and in some patients can reduce the natriuretic effect of furosemide and thiazides.

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, may result in deterioration of renal function, including possible acute renal failure. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

CELEBREX can be used with low-dose aspirin. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.

Concomitant administration of aspirin with CELEBREX increases the rate of GI ulceration or other complications, compared with use of CELEBREX alone.

Treatment with NSAIDs, including CELEBREX, is not recommended in those patients with advanced renal disease. In addition, NSAIDs may cause renal toxicity.

Serious skin reactions such as exfoliative dermatitis, Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported in patients receiving CELEBREX. These reactions can be fatal. They can occur without warning and in patients without prior known sulfa allergy. CELEBREX should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Rare cases of anaphylactic reactions and angioedema have been reported in patients receiving CELEBREX. Patients should seek immediate emergency assistance if they have swelling of the face or throat or have difficulty breathing.

CELEBREX should be avoided in late pregnancy.

NSAIDs, including CELEBREX, should be used with caution in pediatric patients with systemic onset JRA, due to the risk of disseminated intravascular coagulation.

Please see Full Prescribing Information including boxed warning

Indications

CELEBREX is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults; the treatment of primary dysmenorrhea; and for relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older.